The US Food and Drug Administration (FDA) has announced an aggressive timeline to scale use of artificial intelligence (AI) internally across all FDA centres by 30 June 2025, following the completion of a new generative AI pilot for scientific reviewers. “I was blown away by the success of our first AI-assisted scientific review pilot. We […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
